Autolus Therapeutics plc is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Autolus Therapeutics employs 376 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Autolus Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AUTL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Autolus Therapeutics stock price (NASDAQ: AUTL)Use our graph to track the performance of AUTL stocks over time.
Autolus Therapeutics shares at a glance
|Latest market close||$6.63|
|52-week range||$4.60 - $16.78|
|50-day moving average||$6.78|
|200-day moving average||$6.73|
|Wall St. target price||$15.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.40|
Buy Autolus Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Autolus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Autolus Therapeutics price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-0.15%|
|3 months (2021-04-30)||13.92%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Autolus Therapeutics financials
|Revenue TTM||$1.1 million|
|Gross profit TTM||$-133,173,000|
|Return on assets TTM||-22.28%|
|Return on equity TTM||-29.62%|
|Market capitalisation||$389.6 million|
TTM: trailing 12 months
Shorting Autolus Therapeutics shares
There are currently 2.0 million Autolus Therapeutics shares held short by investors – that's known as Autolus Therapeutics's "short interest". This figure is 11.7% down from 2.3 million last month.
There are a few different ways that this level of interest in shorting Autolus Therapeutics shares can be evaluated.
Autolus Therapeutics's "short interest ratio" (SIR)
Autolus Therapeutics's "short interest ratio" (SIR) is the quantity of Autolus Therapeutics shares currently shorted divided by the average quantity of Autolus Therapeutics shares traded daily (recently around 2.2 million). Autolus Therapeutics's SIR currently stands at 0.9. In other words for every 100,000 Autolus Therapeutics shares traded daily on the market, roughly 900 shares are currently held short.
However Autolus Therapeutics's short interest can also be evaluated against the total number of Autolus Therapeutics shares, or, against the total number of tradable Autolus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Autolus Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Autolus Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0591% of the tradable shares (for every 100,000 tradable Autolus Therapeutics shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Autolus Therapeutics.
Find out more about how you can short Autolus Therapeutics stock.
Autolus Therapeutics share dividends
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Autolus Therapeutics share price volatility
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $4.6 up to $16.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 1.6871. This would suggest that Autolus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Autolus Therapeutics overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. .
Stocks similar to Autolus Therapeutics
Autolus Therapeutics in the news
new option listings and one option delisting on July 21st
Autolus: Developing Better CAR-T In Refractory ALL
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
Frequently asked questionsWhat percentage of Autolus Therapeutics is owned by insiders or institutions?
Currently 26.09% of Autolus Therapeutics shares are held by insiders and 36.097% by institutions. How many people work for Autolus Therapeutics?
Latest data suggests 376 work at Autolus Therapeutics. When does the fiscal year end for Autolus Therapeutics?
Autolus Therapeutics's fiscal year ends in September. Where is Autolus Therapeutics based?
Autolus Therapeutics's address is: Forest House, London, United Kingdom, W12 7RZ What is Autolus Therapeutics's ISIN number?
Autolus Therapeutics's international securities identification number is: US05280R1005 What is Autolus Therapeutics's CUSIP number?
Autolus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05280R100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert